HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 51.1%

Neg 51.1% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $24 to $21.